Cited by 2,770Cancer Cells and MetastasisDrug Transport and Resistance MechanismsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 183 of the 188 references it cites were found in a registry or an index.

A view on drug resistance in cancer

Open access

Vasan, Neil, Baselga, José, Hyman, David M.·2019·Nature

DOI 10.1038/s41586-019-1730-1PMC PMC8008476

Open this paper in CoChat — free account Open PDF

Abstract

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1730-1

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Show all 188 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 201–300 of 1,001

Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments
Wang, W., Zheng, H., Jiang, J., Li, Z., Jiang, D., Shi, X., Wang, H., Jiang, J., Xie, Q., Gao, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32066-w · Cited by 81
Cell death shapes cancer immunity: spotlighting PANoptosis
Gao, L., Shay, C., & Teng, Y. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03089-6 · Cited by 86
LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers
Xin, X., Li, Q., Fang, J., & Zhao, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679244 · Cited by 79
Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance
Liu, Y., Ao, X., Wang, Y., Li, X., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841411 · Cited by 80
Rationally designed Ru( ii )-metallacycle chemo-phototheranostic that emits beyond 1000 nm
Li, C., Xu, Y., Tu, L., Choi, M., Fan, Y., Chen, X., Sessler, J. L., Kim, J. S., & Sun, Y. (2022) · Chemical Science · doi:10.1039/d2sc01518h · Cited by 79
Nanoparticle-mediated cancer cell therapy: basic science to clinical applications
Verma, J., Warsame, C., Seenivasagam, R. K., Katiyar, N. K., Aleem, E. A., & Goel, S. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10086-2 · Cited by 84
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Remón, J., Besse, B., Ponce-Aix, S., Callejo, A., Al-Rabi, K., Bernabé, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.012 · Cited by 79
Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options
Gao, H., Xi, Z., Dai, J., Xue, J., Guan, X., Zhao, L., Chen, Z., & Xing, F. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02005-y · Cited by 81
P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators
Guo, Y., Ashrafizadeh, M., Tambuwala, M. M., Ren, J., Orive, G., & Yu, G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104161 · Cited by 84
Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment
Çiftçi, F., Özarslan, A. C., Kantarci, İ. C., Yelkenci, A., Tavukçuoğlu, Ö., & Ghorbanpour, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010121 · Cited by 92
The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer
Yong, L., Tang, S., Yu, H., Zhang, H., Zhang, Y., Wan, Y., & Cai, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964934 · Cited by 83
Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer
Wang, M., Chen, X., Tan, P., Wang, Y., Pan, X., Lin, T., Jiang, Y., Wang, B., Xu, H., Wang, Y., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.010 · Cited by 79
Photo‐facilitated chemodynamic therapeutic agents: Synthesis, mechanisms, and biomedical applications
Yang, N., Cao, C., Lv, X., Zhang, T., Shao, J., Song, X., Wang, W., Chen, P., Huang, W., & Dong, X. (2023) · BMEMat · doi:10.1002/bmm2.12005 · Cited by 78
Soft Bioelectronics for Therapeutics
Zhang, Z., Zhu, Z., Zhou, P., Zou, Y., Yang, J., Haick, H., & Wang, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c02513 · Cited by 79
Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity
Ding, X. Q., Ting, N. L.-N., Wong, C. C., Huang, P., Бакурадзе, Н., Jiang, L., Liu, C., Lin, Y., Li, S., Liu, Y., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.05.004 · Cited by 83
Forkhead Box Transcription Factors: Double-Edged Swords in Cancer
Castañeda, M., den Hollander, P., & Mani, S. A. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3371 · Cited by 77
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Eptaminitaki, G. C., Stellas, D., Bonavida, B., & Baritaki, S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100866 · Cited by 78
Rational development of combination therapies for biliary tract cancers
Harding, J. J., Khalil, D. N., Fabris, L., & Abou‐Alfa, G. K. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.004 · Cited by 80
Functional Nucleic Acids-Engineered Bio-Barcode Nanoplatforms for Targeted Synergistic Therapy of Multidrug-Resistant Cancer
Zhi, S., Zhang, X., Zhang, J., Wang, X., & Bi, S. (2023) · ACS Nano · doi:10.1021/acsnano.3c02009 · Cited by 77
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Palmer, C. L., Boras, B. W., Pascual, B., Li, N., Li, D., Garza, S. J., Huser, N. H., Yuan, J. T., Cianfrogna, J. A., Sung, T., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.006 · Cited by 79
Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis
Lin, P. P. (2020) · Cells · doi:10.3390/cells9061539 · Cited by 78
Flower-like Nanozyme with Highly Porous Carbon Matrix Induces Robust Oxidative Storm against Drug-Resistant Cancer
Xing, Y., Li, L., Chen, Y., Wang, L., Tang, S., Xie, X., Wang, S., Huang, J., Cai, K., & Zhang, J. (2023) · ACS Nano · doi:10.1021/acsnano.2c12698 · Cited by 76
MicroRNA-mediated autophagy regulation in cancer therapy: The role in chemoresistance/chemosensitivity
Ashrafizadeh, M., Zarrabi, A., Orouei, S., Hushmandi, K., Hakimi, A., Zabolian, A., Daneshi, S., Samarghandian, S., Baradaran, B., & Najafi, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173660 · Cited by 76
Smart responsive nanoplatform via in situ forming disulfiram-copper ion chelation complex for cancer combination chemotherapy
Meng, X., Jia, K., Sun, K., Zhang, L., & Wang, Z. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.128947 · Cited by 74
Carbonic Anhydrase IX Inhibitors as Candidates for Combination Therapy of Solid Tumors
Kalinin, S., Михайловна, М. А., Sharonova, T. V., Sharoyko, V. V., Bunev, A. S., Supuran, C. T., & Krasavin, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413405 · Cited by 78
Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy
Cao, L., Zhu, Y., Wang, W., Wang, G., Zhang, S., & Cheng, H. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.798882 · Cited by 75
Heterochiral β-Peptide Polymers Combating Multidrug-Resistant Cancers Effectively without Inducing Drug Resistance
Shao, N., Yuan, L., Ma, P., Zhou, M., Xiao, X., Cong, Z., Wu, Y., Xiao, G., Fei, J., & Liu, R. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00452 · Cited by 73
Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials
Bukhari, S. N. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040866 · Cited by 74
Novel epigenetic therapeutic strategies and targets in cancer
Babar, Q., Saeed, A., Tabish, T. A., Pricl, S., Townley, H. E., & Thorat, N. D. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166552 · Cited by 77
The HER2-low revolution in breast oncology: steps forward and emerging challenges
Nicolò, E., Bielo, L. B., Curigliano, G., & Tarantino, P. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231152842 · Cited by 74
Pharmacological Activity, Pharmacokinetics, and Toxicity of Timosaponin AIII, a Natural Product Isolated From Anemarrhena asphodeloides Bunge: A Review
Lin, Y., Zhao, W.-R., Shi, W., Zhang, J., Zhang, K.-Y., Ding, Q., Chen, X., Tang, J., & Zhou, Z.-Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00764 · Cited by 73
FOXO3a in cancer drug resistance
Liu, Y., Wang, Y., Li, X., Jia, Y., Wang, J., & Ao, X. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215724 · Cited by 72
Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products
Cheng, X., Yan, H., Pang, S., Ya, M., Qiu, F., Qin, P., Zeng, C., & Lu, Y. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.963004 · Cited by 72
DRESIS: the first comprehensive landscape of drug resistance information
Sun, X., Zhang, Y., Li, H., Zhou, Y., Shi, S., Chen, Z., He, X., Zhang, H., Li, F., Yin, J., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac812 · Cited by 73
Exosome derived from tumor-associated macrophages: biogenesis, functions, and therapeutic implications in human cancers
Zhou, M., He, X., Mei, C., & Ou, C. (2023) · Biomarker Research · doi:10.1186/s40364-023-00538-w · Cited by 74
Chronic Inflammation and Blood CancerPreprint
Tzenios, N., Tazanios, M., & Chahine, M. A. (2022) · Preprints.org · doi:10.20944/preprints202211.0365.v1 · Cited by 72
Latest research progress on anticancer effect of baicalin and its aglycone baicalein
Wang, L., Feng, T., Su, Z., Pi, C., Wei, Y., & Zhao, L. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01397-z · Cited by 76
The Cancer Antioxidant Regulation System in Therapeutic Resistance
Gu, X., Mu, C., Zheng, R., Zhang, Z., Zhang, Q., & Liang, T. (2024) · Antioxidants · doi:10.3390/antiox13070778 · Cited by 79
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 74
Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers
Kanno, Y., Chen, C.-Y., Lee, H.-L., Chiou, J.-F., & Chen, Y.-J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640392 · Cited by 80
Delivery of therapeutic oligonucleotides in nanoscale
Wu, L., Zhou, W., Lin, L., Chen, A., Feng, J. C., Qu, X., Zhang, H., & Yue, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.038 · Cited by 72
Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line
Pudewell, S., Wittich, C., Jasemi, N. S. K., Bazgir, F., & Ahmadian, M. R. (2021) · Communications Biology · doi:10.1038/s42003-021-02149-3 · Cited by 75
A Near‐Infrared Light‐Responsive ROS Cascade Nanoplatform for Synergistic Therapy Potentiating Antitumor Immune Responses
Cen, D., Zheng, Q., Zheng, B., Zhou, R., Xiao, X., Zhang, T., Huang, Z., Yan, T., Yu, J., Li, X., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202211402 · Cited by 70
Drug resistance in glioblastoma: are persisters the key to therapy?
Oliver, L., Lalier-Bretaudeau, L., Salaud, C., Heymann, D., Cartron, P., & Vallette, F. M. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.29 · Cited by 71
Injectable and pH-responsive self-assembled peptide hydrogel for promoted tumor cell uptake and enhanced cancer chemotherapy
Zhang, J., Lin, W., Yang, L., Zhang, A., Zhang, Y., Liu, J., & Liu, J. (2022) · Biomaterials Science · doi:10.1039/d1bm01788h · Cited by 69
Post-translational modifications in drug resistance
Miao, C., Huang, Y., Zhang, C., Wang, X., Wang, B., Zhou, X., Song, Y., Wu, P., Chen, Z., & Feng, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101173 · Cited by 75
Erianin inhibits human lung cancer cell growth via PI3K /Akt/ mTOR pathway in vitro and in vivo
Zhang, H., Xie, X., Li, G., Chen, J., Li, M., Xu, X., Xiong, Q., Chen, G., Yin, Y., Peng, F., et al. (2021) · Phytotherapy Research · doi:10.1002/ptr.7154 · Cited by 68
Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery
Huang, L., Jianmiao, Y., Wang, T., Gao, J., & Xu, D. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01257-4 · Cited by 70
Multimodal Decorations of Mesoporous Silica Nanoparticles for Improved Cancer Therapy
Barui, S., & Cauda, V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060527 · Cited by 73
Self-Motivated Supramolecular Combination Chemotherapy for Overcoming Drug Resistance Based on Acid-Activated Competition of Host–Guest Interactions
Wang, H., Wu, H., Yi, Y., Xue, K.-F., Xu, J., Wang, H., Zhao, Y., & Zhang, X. (2021) · CCS Chemistry · doi:10.31635/ccschem.021.202100964 · Cited by 67
Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective
Jin, M. L., & Jeong, K. W. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01014-z · Cited by 69
Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems
Lainetti, P. D. F., Leis‐Filho, A. F., Amorim, R. L., Battazza, A., & Fonseca‐Alves, C. E. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121193 · Cited by 66
The Photosensitizer Temoporfin ( m THPC ) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade † ‡
Wiehe, A., & Senge, M. O. (2022) · Photochemistry and Photobiology · doi:10.1111/php.13730 · Cited by 70
Mutation–selection balance and compensatory mechanisms in tumour evolution
Persi, E., Wolf, Y. I., Horn, D., Ruppin, E., Demichelis, F., Gatenby, R. A., Gillies, R. J., & Koonin, E. V. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-00299-4 · Cited by 64
Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives
Ruiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65
Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
Yi, K., Kong, H., Lao, Y., Li, D., Mintz, R. L., Fang, T., Chen, G., Tao, Y., Li, M., & Ding, J. (2023) · Advanced Materials · doi:10.1002/adma.202300665 · Cited by 66
Composite scaffolds of black phosphorus nanosheets and gelatin with controlled pore structures for photothermal cancer therapy and adipose tissue engineering
Sutrisno, L., Chen, H., Chen, Y., Yoshitomi, T., Kawazoe, N., Yang, Y., & Chen, G. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120923 · Cited by 64
Multifunctional nano MOF drug delivery platform in combination therapy
Ma, D., Wang, G., Lu, J.-S., Zeng, X., Cheng, Y., Zhang, Z., Lin, N., & Chen, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115884 · Cited by 66
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
Zhao, J., Xu, W., Zhou, F., Zhang, X., Zhou, M., Miao, D., Yu, L., Zhang, Y., Fan, J., Zhou, C., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01085-z · Cited by 68
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Impact of Galectins in Resistance to Anticancer Therapies
Navarro, P., Martínez‐Bosch, N., Blidner, A. G., & Rabinovich, G. A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3870 · Cited by 65
Polo-Like Kinase 4’s Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy
Zhang, X., Wei, C., Liang, H., & Han, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.587554 · Cited by 61
Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA
Yuan, Y., Liu, J., Yu, X., Liu, X., Cheng, Y., Zhou, C., Li, M., Shi, L., Deng, Y., Liu, H., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.09.002 · Cited by 63
Silver Nanoparticles from Annona muricata Peel and Leaf Extracts as a Potential Potent, Biocompatible and Low Cost Antitumor Tool
González-Pedroza, M. G., Argueta‐Figueroa, L., García‐Contreras, R., Jiménez-Martínez, Y., Martínez‐Martínez, E., Navarro-Marchal, S. A., Marchal, J. A., Morales‐Luckie, R. A., & Boulaiz, H. (2021) · Nanomaterials · doi:10.3390/nano11051273 · Cited by 66
METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation
Bhattarai, P. Y., Kim, G., Poudel, M., Lim, S., & Choi, H. S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.015 · Cited by 62
Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis
Homayoonfal, M., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00320-0 · Cited by 64
RETRACTED: Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation
Mirzaei, S., Gholami, M. H., Mahabady, M. K., Nabavi, N., Zabolian, A., Banihashemi, S. M., Haddadi, A., Entezari, M., Hushmandi, K., Makvandi, P., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111077 · Cited by 61
Retracted
Cancer stem cells in colorectal cancer and the association with chemotherapy resistance
Lei, X., He, Q., Li, Z., Zou, Q., Xu, P., Yu, H., Ding, Y., & Zhu, W. (2021) · Medical Oncology · doi:10.1007/s12032-021-01488-9 · Cited by 62
Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy
Tang, Y., Wang, L., Yi, T., Xu, J., Wang, J., Qin, J., Chen, Q., Yip, K.-M., Pan, Y., Peng, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.007 · Cited by 61
Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer
Murillo, D., Huergo, C., Gallego, B., Rodrı́guez, R., & Tornín, J. (2023) · Biomedicines · doi:10.3390/biomedicines11010208 · Cited by 65
Base editing screens define the genetic landscape of cancer drug resistance mechanisms
Coelho, M. A., Strauß, M. E., Watterson, A., Cooper, S., Bhosle, S. G., Illuzzi, G., Karakoç, E., Dinçer, C., Vieira, S. F., Sharma, M., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01948-8 · Cited by 65
Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes
D’Esposito, V., Ambrosio, M. R., Giuliano, M., Cabaro, S., Miele, C., Bèguinot, F., & Formisano, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01554 · Cited by 65
Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma
Farshadi, E. A., Chang, J., Sampadi, B. K., Doukas, M., Land, F. R. V. ‘., van der Sijde, F., Vietsch, E. E., Pothof, J., Koerkamp, B. G., & van Eijck, C. H. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1681 · Cited by 60
Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy
Hao, Y., Chung, C. K., Yu, Z., Veld, R. V. H. I. ‘., OSSENDORP, F. A., ten Dijke, P., & Cruz, L. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010120 · Cited by 60
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Park, S. J., Yoo, H. C., Ahn, E., Luo, E., Kim, Y., Sung, Y., Yu, Y. C., Kim, K., Min, D. S., Lee, H. S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2045 · Cited by 63
Resveratrol, Epigallocatechin Gallate and Curcumin for Cancer Therapy: Challenges from Their Pro-Apoptotic Properties
Chimento, A., D’Amico, M., Luca, A. D., Conforti, F. L., Pezzi, V., & Amicis, F. D. (2023) · Life · doi:10.3390/life13020261 · Cited by 65
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Ming, H., Li, B., Jiang, J., Qin, S., Nice, E. C., He, W., Lang, T., & Huang, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01398-5 · Cited by 64
Tumor microenvironment-tailored nanoplatform for companion diagnostic applications of precise cancer therapy
Lu, C., Li, Z., Wu, N., Lu, D., Zhang, X., & Song, G. (2023) · Chem · doi:10.1016/j.chempr.2023.06.011 · Cited by 60
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Koirala, M., & DiPaola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081801 · Cited by 68
Synthesis of New 1, 3, 4-Oxadiazole-Incorporated 1, 2, 3-Triazole Moieties as Potential Anticancer Agents Targeting Thymidylate Synthase and Their Docking Studies
Alam, M. M., Almalki, A. S. A., Neamatallah, T., Ali, N. M., Malebari, A. M., & Nazreen, S. (2020) · Pharmaceuticals · doi:10.3390/ph13110390 · Cited by 60
A tumor microenvironment responsive nanoplatform with oxidative stress amplification for effective MRI-based visual tumor ferroptosis
Luo, S., Ma, D., Wei, R., Wang, Y., Pang, X., Wang, Y., Xu, X., Wei, X., Guo, Y., Jiang, X., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.11.007 · Cited by 59
Clinical applications of plasma proteomics and peptidomics: Towards precision medicine
He, B., Huang, Z., Huang, C., & Nice, E. C. (2022) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202100097 · Cited by 60
Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors
Guo, Z., Sun, Y., Liang, L., Lu, W., Luo, B., Wu, Z., Huo, B., Hu, Y., Huang, P., Wu, Q., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01876 · Cited by 59
Ligand based pharmacophore modelling and integrated computational approaches in the quest for small molecule inhibitors against hCA IX
Saravanan, V., Chagaleti, B. K., Packiapalavesam, S. D., & Kathiravan, M. (2024) · RSC Advances · doi:10.1039/d3ra08618f · Cited by 63
Intracellular Photocatalytic NADH/NAD(P)H Oxidation for Cancer Drug Development
Yadav, A. K., Kushwaha, R., Mandal, A. A., Mandal, A., & Banerjee, S. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18328 · Cited by 59
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zou, Z., Yang, L., Nie, H., Gao, J., Lei, S., Lai, Y., Zhang, F., Wagner, E., Yu, H., Chen, X., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01266-z · Cited by 65
Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations
AlDoughaim, M., Alsuhebany, N., Alzahrani, M., Alqahtani, T., Alghamdi, S. S., Badreldin, H. A., & Alshaykh, H. A. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241298541 · Cited by 68
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
Li, W., Guo, H., Li, L., Zhang, Y., & Cui, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4052 · Cited by 59
Mitochondrial temperature-responsive drug delivery reverses drug resistance in lung cancer
Ruan, L., Chen, J., Du, C., Lu, H., Zhang, J., Cai, X., Dou, R., Lin, W., Chai, Z., Nie, G., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.045 · Cited by 60
Nanoparticles Loaded with Docetaxel and Resveratrol as an Advanced Tool for Cancer Therapy
Jurczyk, M., Kasperczyk, J., Wrześniok, D. M., Beberok, A., & Jelonek, K. (2022) · Biomedicines · doi:10.3390/biomedicines10051187 · Cited by 61
The role of Hedgehog and Notch signaling pathway in cancer
Xia, R., Xu, M., Yang, J., & Ma, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00099-8 · Cited by 62
Intratumoral Microbiota as a Target for Advanced Cancer Therapeutics
Peng, F., Hu, M., Su, Z., Hu, L., Guo, L., & Yang, K. (2024) · Advanced Materials · doi:10.1002/adma.202405331 · Cited by 57
The future of tumor organoids in precision therapy
Kim, S., van de Wetering, M., Clevers, H. C., & Sanders, K. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.03.005 · Cited by 62
Recent advances in microfluidic technology and applications for anti-cancer drug screening
Shi, Y., Cai, Y., Cao, Y., Hong, Z., & Chai, Y. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.116118 · Cited by 60
Exploring liver cancer biology through functional genetic screens
Wang, C., Cao, Y., Yang, C. G., Bernards, R., & Qin, W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00465-x · Cited by 58
Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?
Zuo, S., Song, J., Zhang, J., He, Z., Sun, B., & Sun, J. (2021) · Theranostics · doi:10.7150/thno.59953 · Cited by 56
Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
Lavallée, É., Sfakianos, J. P., & Mulholland, D. J. (2021) · Cancers · doi:10.3390/cancers13215297 · Cited by 60
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Zhang, J., Zhang, J., Liu, Q., Fan, X., Leung, E. L., Yao, X., & Liu, L. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108050 · Cited by 57
Molecular mechanisms associated with chemoresistance in esophageal cancer
Lohan-Codeço, M., Barambo-Wagner, M. L., Nasciutti, L. E., Pinto, L. F. R., Costa, N. M. D., & Palumbo, A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04131-6 · Cited by 61

Authors: Vasan, N., Baselga, J., & Hyman, D. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Hyman, David M.
ORCID: Vasan, Neil
Hyman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-11-13
Volume: 575
Issue: 7782
Pages: 299-309
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1730-1
PMC: PMC8008476
OpenAlex: W2988773550
Cited by: 2,770
References: 188
Citations by year: 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
FWCI: 21.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Eli Lilly and Company
National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
MeSH terms: Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A view on drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks